作者
Carolina Schinke, Antje Hoering, Hongwei Wang, Victoria Carlton, Sharmilan Thanandrarajan, Shayu Deshpande, Purvi Patel, Gabor Molnar, Sandra Susanibar, Meera Mohan, Pankaj Mathur, Muthukumar Radhakrishnan, Shadiqul Hoque, Jorge Jo Kamimoto, Monica Grazziutti, Frits van Rhee, Maurizio Zangari, Giovanni Insuasti-Beltran, Daisy Alapat, Ginell Post, Shmuel Yaccoby, Joshua Epstein, Leo Rasche, Sarah Johnson, Martin Moorhead, Tom Willis, Bart Barlogie, Brian Walker, Niels Weinhold, Faith E Davies, Gareth J Morgan
发表日期
2017/8
期刊
Haematologica
卷号
102
期号
8
页码范围
e313
出版商
Ferrata Storti Foundation
简介
Complete remission (CR) rates for multiple myeloma (MM) have increased to 60% with current treatment approaches, including high dose melphalan-based autologous stem cell transplant (ASCT) and novel agents, and are associated with improved survival. 1-3 Despite this improvement, highly sensitive methods to detect minimal residual disease (MRD), including multiparameter flow-cytometry (MFC), allele-specific oligonucleotide polymerase chain reaction (ASO-PCR), and next generation sequencing (NGS) have shown that residual tumor cells persist in these states. 4, 5 Achieving MRD negativity at a level of 10-5 to 10-6 has been associated with improved progression free (PFS) and overall survival (OS) suggesting that being negative at this level could constitute a therapeutic endpoint. 6-8
Applying clinical tools for CR assessment, we have shown that there are profound differences in the time to maximum …
学术搜索中的文章
C Schinke, A Hoering, H Wang, V Carlton… - Haematologica, 2017